| Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia OA Cornely, J Maertens, DJ Winston, J Perfect, AJ Ullmann, TJ Walsh, ... New England Journal of Medicine 356 (4), 348-359, 2007 | 2147 | 2007 |
| Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group … OA Cornely, A Alastruey-Izquierdo, D Arenz, SCA Chen, E Dannaoui, ... The Lancet infectious diseases 19 (12), e405-e421, 2019 | 1659 | 2019 |
| Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, ... Clinical Microbiology and Infection 24, e1-e38, 2018 | 1469 | 2018 |
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients OA Cornely, M Bassetti, T Calandra, J Garbino, BJ Kullberg, O Lortholary, ... Clinical Microbiology and Infection 18, 19-37, 2012 | 1388 | 2012 |
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia TJ Walsh, H Teppler, GR Donowitz, JA Maertens, LR Baden, ... New England Journal of Medicine 351 (14), 1391-1402, 2004 | 1201 | 2004 |
| Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled … JA Maertens, II Raad, KA Marr, TF Patterson, DP Kontoyiannis, ... The Lancet 387 (10020), 760-769, 2016 | 969 | 2016 |
| Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial OA Cornely, DW Crook, R Esposito, A Poirier, MS Somero, K Weiss, ... The Lancet infectious diseases 12 (4), 281-289, 2012 | 933 | 2012 |
| Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection MH Wilcox, DN Gerding, IR Poxton, C Kelly, R Nathan, T Birch, ... New England Journal of Medicine 376 (4), 305-317, 2017 | 894 | 2017 |
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial ER Kuse, P Chetchotisakd, CA da Cunha, M Ruhnke, C Barrios, ... The Lancet 369 (9572), 1519-1527, 2007 | 891 | 2007 |
| Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ... The Lancet Infectious Diseases 21 (6), e149-e162, 2021 | 851 | 2021 |
| Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad Trial) OA Cornely, J Maertens, M Bresnik, R Ebrahimi, AJ Ullmann, E Bouza, ... Clinical infectious diseases 44 (10), 1289-1297, 2007 | 847 | 2007 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 839 | 2021 |
| ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013 OA Cornely, S Arikan‐Akdagli, E Dannaoui, AH Groll, K Lagrou, ... Clinical Microbiology and Infection 20, 5-26, 2014 | 779 | 2014 |
| Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis FM Marty, L Ostrosky-Zeichner, OA Cornely, KM Mullane, JR Perfect, ... The Lancet infectious diseases 16 (7), 828-837, 2016 | 719 | 2016 |
| Tackling the emerging threat of antifungal resistance to human health MC Fisher, A Alastruey-Izquierdo, J Berman, T Bicanic, EM Bignell, ... Nature reviews microbiology 20 (9), 557-571, 2022 | 713 | 2022 |
| COVID‐19 associated pulmonary aspergillosis P Koehler, OA Cornely, BW Böttiger, F Dusse, DA Eichenauer, F Fuchs, ... Mycoses 63 (6), 528-534, 2020 | 635 | 2020 |
| European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update J Maertens, O Marchetti, R Herbrecht, OA Cornely, U Flückiger, P Frere, ... Bone marrow transplantation 46 (5), 709-718, 2011 | 623 | 2011 |
| Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials S Johnson, TJ Louie, DN Gerding, OA Cornely, S Chasan-Taber, D Fitts, ... Clinical Infectious Diseases 59 (3), 345-354, 2014 | 603 | 2014 |
| Combination antifungal therapy for invasive aspergillosis: a randomized trial KA Marr, HT Schlamm, R Herbrecht, ST Rottinghaus, EJ Bow, OA Cornely, ... Annals of internal medicine 162 (2), 81-89, 2015 | 566 | 2015 |
| Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin OA Cornely, MA Miller, TJ Louie, DW Crook, SL Gorbach Clinical infectious diseases 55 (suppl_2), S154-S161, 2012 | 541 | 2012 |
Jörg Janne VehreschildProfessor of Digital Medicine und Clinical Data Science, Goethe University Frankfurt, Germanymed.uni-frankfurt.de의 이메일 확인됨